Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00175916
Status:
COMPLETED
Last Update Posted:
2021-08-17
First Post:
2005-09-09
Brief Title:
Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
An Open-label Multicenter Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mgDay in Subjects Aged 16 Years or Older Suffering From Epilepsy
Status:
COMPLETED
Status Verified Date:
2021-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT03532516
Has Expanded Access, NCT# Status:
AVAILABLE
Acronym:
None
Brief Summary:
This trial evaluating the long-term safety and tolerability of brivaracetam will give subjects suffering from epilepsy who may have benefited from brivaracetam the opportunity to continue the treatment The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjects with partial onset seizures POSprimary generalized seizures PGS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-002140-10 | EUDRACT_NUMBER | None | None |